Krystal Biotech (KRYS) Non Operating Income (2017 - 2026)

Krystal Biotech (KRYS) has 7 years of Non Operating Income data on file, last reported at $7.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 5.55% year-over-year to $7.8 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (down 2.32% YoY), and the FY2025 full-year result was $28.2 million, down 4.84% from the prior year.
• Non Operating Income grew to $7.8 million in Q1 2026, from $6.9 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $7.8 million in Q1 2026 to a low of $6.6 million in Q3 2025.
• A 4-year average of $7.3 million and a median of $7.3 million in 2025 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income rose 8.26% in 2024 and declined 9.65% in 2025, its largest moves.
• Tracing KRYS's Non Operating Income over 4 years: stood at $7.4 million in 2023, then fell by 2.35% to $7.2 million in 2024, then retreated by 5.17% to $6.9 million in 2025, then advanced by 13.0% to $7.8 million in 2026.
• Business Quant data shows KRYS's Non Operating Income at $7.8 million in Q1 2026, $6.9 million in Q4 2025, and $6.6 million in Q3 2025.